Literature DB >> 22220471

Structure and regulation of type 2 transglutaminase in relation to its physiological functions and pathological roles.

Carlo M Bergamini1, Russell J Collighan, Zhuo Wang, Martin Griffin.   

Abstract

Mesh：

Substances：

Year:  2011        PMID： 22220471     DOI： 10.1002/9781118105771.ch1

Source DB:  PubMed          Journal:  Adv Enzymol Relat Areas Mol Biol        ISSN： 0065-258X


× No keyword cloud information.
  10 in total

1.  Expression of Functional Recombinant Human Tissue Transglutaminase (TG2) Using the Bac-to-Bac Baculovirus Expression System.

Authors:  Yaghoub Yazdani; Shahram Azari; Hamid Reza Kalhor
Journal:  Adv Pharm Bull       Date:  2016-03-17

2.  Transglutaminase 2 induces intrinsic EGFR-TKI resistance in NSCLC harboring EGFR sensitive mutations.

Authors:  Junyoung Choi; Shinkyo Yoon; Deokhoon Kim; Yong Wha Moon; Chang Hoon Lee; Seyoung Seo; Jaekyung Cheon; Yong Song Gho; Changhoon Kim; Eung Ryoung Lee; Soo-Youl Kim; Kyoungmin Lee; Joo Young Ha; Sook Ryun Park; Sang-We Kim; Kang-Seo Park; Dae Ho Lee
Journal:  Am J Cancer Res       Date:  2019-08-01       Impact factor: 6.166

3.  Changes in protein expression in two cholangiocarcinoma cell lines undergoing formation of multicellular tumor spheroids in vitro.

Authors:  Carlo Mischiati; Blendi Ura; Leda Roncoroni; Luca Elli; Carlo Cervellati; Monica Squerzanti; Dario Conte; Luisa Doneda; Patrizia Polverino de Laureto; Giorgia de Franceschi; Roberta Calza; Carlos A Barrero; Salim Merali; Carlo Ferrari; Carlo M Bergamini; Enzo Agostinelli
Journal:  PLoS One       Date:  2015-03-10       Impact factor: 3.240

4.  Tissue transglutaminase (TG2) enables survival of human malignant pleural mesothelioma cells in hypoxia.

Authors:  Sara Zonca; Giulia Pinton; Zhuo Wang; Maria Felicia Soluri; Daniela Tavian; Martin Griffin; Daniele Sblattero; Laura Moro
Journal:  Cell Death Dis       Date:  2017-02-02       Impact factor: 8.469

5.  Transglutaminase 2: a novel therapeutic target for idiopathic pulmonary fibrosis using selective small molecule inhibitors.

Authors:  Shaun Fell; Zhuo Wang; Andy Blanchard; Carmel Nanthakumar; Martin Griffin
Journal:  Amino Acids       Date:  2021-01-21       Impact factor: 3.520

6.  Mapping the metabolomic and lipidomic changes in the bleomycin model of pulmonary fibrosis in young and aged mice.

Authors:  Jelena Weckerle; Sergio Picart-Armada; Stephan Klee; Tom Bretschneider; Andreas H Luippold; Wolfgang Rist; Christian Haslinger; Holger Schlüter; Matthew J Thomas; Bartlomiej Krawczyk; Francesc Fernandez-Albert; Marc Kästle; Daniel Veyel
Journal:  Dis Model Mech       Date:  2022-01-25       Impact factor: 5.758

7.  Dysregulation of Transglutaminase type 2 through GATA3 defines aggressiveness and Doxorubicin sensitivity in breast cancer.

Authors:  Gianluca Aguiari; Francesca Crudele; Cristian Taccioli; Linda Minotti; Fabio Corrà; Jeffrey W Keillor; Silvia Grassilli; Carlo Cervellati; Stefano Volinia; Carlo M Bergamini; Nicoletta Bianchi
Journal:  Int J Biol Sci       Date:  2022-01-01       Impact factor: 6.580

8.  Characterization of distinct sub-cellular location of transglutaminase type II: changes in intracellular distribution in physiological and pathological states.

Authors:  Mauro Piacentini; Manuela D'Eletto; Maria Grazia Farrace; Carlo Rodolfo; Franca Del Nonno; Giuseppe Ippolito; Laura Falasca
Journal:  Cell Tissue Res       Date:  2014-09-11       Impact factor: 5.249

9.  Characterisation of a novel cold-adapted calcium-activated transglutaminase: implications for medicine and food processing.

Authors:  Rebeca Garcia Alvarez; Pralav Karki; Ida Elise Langleite; Ragna-Johanne Bakksjø; Lutz Andreas Eichacker; Clemens Furnes
Journal:  FEBS Open Bio       Date:  2020-03-16       Impact factor: 2.693

10.  Neurite outgrowth inhibitory levels of organophosphates induce tissue transglutaminase activity in differentiating N2a cells: evidence for covalent adduct formation.

Authors:  Ibtesam S Almami; Maha A Aldubayan; Shatha G Felemban; Najiah Alyamani; Richard Howden; Alexander J Robinson; Tom D Z Pearson; David Boocock; Alanood S Algarni; A Christopher Garner; Martin Griffin; Philip L R Bonner; Alan J Hargreaves
Journal:  Arch Toxicol       Date:  2020-08-04       Impact factor: 6.168
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.